Is LEXX or HYPD more profitable?

Hyperion DeFi's return on equity of -91.59% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -206.02% -162.53% Hyperion DeFi N/A -91.59% -73.08%

Which has preferable valuation and earnings, IMMP or LEXX?

Lexaria Bioscience has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 9.14 -$39.78M N/A N/A Lexaria Bioscience $368K 37.72 -$11.90M -$0.47 N/A

Is IMMP or LEXX more profitable?

Prima BioMed's return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Lexaria Bioscience N/A -206.02% -162.53%

Do analysts prefer LEXX or TCRT?

Lexaria Bioscience presently has a consensus target price of $1.50, suggesting a potential upside of 167.86%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LEXX or TCRT more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -206.02% -162.53% Alaunos Therapeutics N/A -165.94% -123.50%

Is PDSB or LEXX more profitable?

Lexaria Bioscience's return on equity of -206.02% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Lexaria Bioscience N/A -206.02% -162.53%

Lexaria Bioscience (LEXX) Competitors

$0.56 0.00 (-0.83%)

As of 03:16 PM Eastern

Compare

LEXX vs. TCRX, HYPD, IMMP, TCRT, and PDSB

Should you buy Lexaria Bioscience stock or one of its competitors? MarketBeat compares Lexaria Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexaria Bioscience include TScan Therapeutics (TCRX), Hyperion DeFi (HYPD), Prima BioMed (IMMP), Alaunos Therapeutics (TCRT), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry.

How does Lexaria Bioscience compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Lexaria Bioscience has lower revenue, but higher earnings than TScan Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$9.14M	7.12	-$129.77M	-$0.96	N/A
Lexaria Bioscience	$368K	37.72	-$11.90M	-$0.47	N/A

Lexaria Bioscience has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Lexaria Bioscience	N/A	-206.02%	-162.53%

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, TScan Therapeutics had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for TScan Therapeutics and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.62 beat TScan Therapeutics' score of 0.38 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
TScan Therapeutics	Neutral
Lexaria Bioscience	Positive

TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 503.02%. Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 167.86%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

TScan Therapeutics beats Lexaria Bioscience on 10 of the 16 factors compared between the two stocks.

How does Lexaria Bioscience compare to Hyperion DeFi?

Lexaria Bioscience (NASDAQ:LEXX) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Hyperion DeFi had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Hyperion DeFi and 1 mentions for Lexaria Bioscience. Hyperion DeFi's average media sentiment score of 1.07 beat Lexaria Bioscience's score of 0.62 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Positive
Hyperion DeFi	Positive

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexaria Bioscience has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market.

Lexaria Bioscience has higher earnings, but lower revenue than Hyperion DeFi. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$368K	37.72	-$11.90M	-$0.47	N/A
Hyperion DeFi	$1.04M	45.05	-$45.31M	-$9.95	N/A

Lexaria Bioscience currently has a consensus price target of $1.50, suggesting a potential upside of 167.86%. Hyperion DeFi has a consensus price target of $5.65, suggesting a potential upside of 82.26%. Given Lexaria Bioscience's higher probable upside, equities research analysts plainly believe Lexaria Bioscience is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Hyperion DeFi's return on equity of -91.59% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-206.02%	-162.53%
Hyperion DeFi	N/A	-91.59%	-73.08%

Summary

Hyperion DeFi beats Lexaria Bioscience on 11 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Prima BioMed had 8 more articles in the media than Lexaria Bioscience. MarketBeat recorded 9 mentions for Prima BioMed and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.62 beat Prima BioMed's score of 0.19 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Prima BioMed	Neutral
Lexaria Bioscience	Positive

Prima BioMed currently has a consensus price target of $5.50, indicating a potential upside of 1,225.30%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 167.86%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	9.14	-$39.78M	N/A	N/A
Lexaria Bioscience	$368K	37.72	-$11.90M	-$0.47	N/A

Prima BioMed's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Lexaria Bioscience	N/A	-206.02%	-162.53%

Prima BioMed has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Summary

Prima BioMed beats Lexaria Bioscience on 6 of the 11 factors compared between the two stocks.

How does Lexaria Bioscience compare to Alaunos Therapeutics?

Lexaria Bioscience (NASDAQ:LEXX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Alaunos Therapeutics has lower revenue, but higher earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$368K	37.72	-$11.90M	-$0.47	N/A
Alaunos Therapeutics	$3K	18,927.05	-$4.18M	-$2.13	N/A

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lexaria Bioscience has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its share price is 207% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -165.94% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-206.02%	-162.53%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 1 mentions for Lexaria Bioscience. Alaunos Therapeutics' average media sentiment score of 0.65 beat Lexaria Bioscience's score of 0.62 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Positive
Alaunos Therapeutics	Positive

Lexaria Bioscience presently has a consensus target price of $1.50, suggesting a potential upside of 167.86%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Alaunos Therapeutics beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Lexaria Bioscience's return on equity of -206.02% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Lexaria Bioscience	N/A	-206.02%	-162.53%

In the previous week, PDS Biotechnology and PDS Biotechnology both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.62 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
Lexaria Bioscience	Positive

PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 919.25%. Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 167.86%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Lexaria Bioscience	$368K	37.72	-$11.90M	-$0.47	N/A

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PDS Biotechnology beats Lexaria Bioscience on 8 of the 13 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.88M	$3.65B	$6.78B	$12.58B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-1.19	21.25	27.32	24.86
Price / Sales	37.72	340.58	561.22	117.20
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	4.31	8.81	11.08	6.58
Net Income	-$11.90M	$23.81M	$3.57B	$336.70M
7 Day Performance	-1.32%	4.01%	2.62%	3.29%
1 Month Performance	-6.98%	1.98%	0.95%	1.72%
1 Year Performance	-35.63%	70.53%	37.04%	31.91%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	1.6832 of 5 stars	$0.56 -0.8%	$1.50 +166.0%	-33.0%	$13.98M	$368K	N/A	7	Gap Down
TCRX TScan Therapeutics	4.1929 of 5 stars	$0.92 +6.5%	$6.00 +551.5%	-30.2%	$56.53M	$10.32M	N/A	100
HYPD Hyperion DeFi	3.6846 of 5 stars	$3.67 -1.1%	$5.65 +54.0%	-70.8%	$56.24M	$810K	N/A	40	Positive News
IMMP Prima BioMed	1.8404 of 5 stars	$0.39 +4.4%	$5.50 +1,296.3%	-75.1%	$55.59M	$6.69M	N/A	2,021
TCRT Alaunos Therapeutics	0.946 of 5 stars	$2.15 -0.5%	N/A	-53.8%	$52.75M	N/A	N/A	40	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TCRX, HYPD, IMMP, TCRT, and PDSB

How does Lexaria Bioscience compare to TScan Therapeutics?

Summary

How does Lexaria Bioscience compare to Hyperion DeFi?

Summary

How does Lexaria Bioscience compare to Prima BioMed?

Summary

How does Lexaria Bioscience compare to Alaunos Therapeutics?

Summary

How does Lexaria Bioscience compare to PDS Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TCRX, HYPD, IMMP, TCRT, and PDSB

How does Lexaria Bioscience compare to TScan Therapeutics?

Which has stronger earnings & valuation, TCRX or LEXX?

Is TCRX or LEXX more profitable?

Do insiders & institutionals believe in TCRX or LEXX?

Which has more volatility & risk, TCRX or LEXX?

Does the media refer more to TCRX or LEXX?

Do analysts prefer TCRX or LEXX?

Summary

How does Lexaria Bioscience compare to Hyperion DeFi?

Does the media favor LEXX or HYPD?

Do insiders and institutionals hold more shares of LEXX or HYPD?

Which has more volatility & risk, LEXX or HYPD?

Which has stronger earnings and valuation, LEXX or HYPD?

Do analysts recommend LEXX or HYPD?

Is LEXX or HYPD more profitable?

Summary

How does Lexaria Bioscience compare to Prima BioMed?

Does the media refer more to IMMP or LEXX?

Do analysts recommend IMMP or LEXX?

Do insiders and institutionals have more ownership in IMMP or LEXX?

Which has preferable valuation and earnings, IMMP or LEXX?

Is IMMP or LEXX more profitable?

Which has more risk & volatility, IMMP or LEXX?

Summary

How does Lexaria Bioscience compare to Alaunos Therapeutics?

Which has stronger valuation and earnings, LEXX or TCRT?

Do insiders and institutionals hold more shares of LEXX or TCRT?

Which has more risk & volatility, LEXX or TCRT?

Is LEXX or TCRT more profitable?

Does the media favor LEXX or TCRT?

Do analysts prefer LEXX or TCRT?

Summary

How does Lexaria Bioscience compare to PDS Biotechnology?

Is PDSB or LEXX more profitable?

Does the media refer more to PDSB or LEXX?

Which has more risk & volatility, PDSB or LEXX?

Do analysts recommend PDSB or LEXX?

Which has preferable earnings & valuation, PDSB or LEXX?

Do institutionals and insiders hold more shares of PDSB or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools